🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

307 results for “Disc Medicine” Clear

  1. Erbitux 5 mg/mL solution for infusion

    Disc Medicine

    Unknown primary tumour of the head and neck

    phase 2 small molecule active

    1 trial

  2. Esmolol HCl LYO Orpha 2500 mg poeder voor concentraat voor oplossing voor infusie, Milrinon Hikma 1 mg/ml oplossing voor injectie, Dobutamine-hameln 5 mg/ml i.v. infusievloeistof, oplossing voor infusie

    Disc Medicine

    Cardiogenic shock

    phase 2 small molecule active

    1 trial

  3. Fianlimab, LIBTAYO 350 mg concentrate for solution for infusion.

    Disc Medicine

    Metastatic solid tumors, these may include but are not limited to melanoma, non-small-cell lung carcinoma (NSCLC), cervical cancer, microsatellite instable (MSI)-high/deficient mismatch repair (dMMR) cancer, renal cell carcinoma (RCC), CSCC, urothelial cell carcer (UCC), small cell lung cancer (SCLC) and head and neck squamous cell carcinoma (HNSCC).

    phase 2 small molecule active

    1 trial

  4. Folinezuur Kalceks 10 mg/ml oplossing voor injectie/infusie, Paclitaxel Fresenius Kabi 6 mg/ml concentraat voor oplossing voor infusie, Carboplatin Accord 10 mg/ml, concentraat voor oplossing voor infusie, Docetaxel Eugia 20 mg/ml, concentraat voor oplossing voor intraveneuze infusie, Fluorouracil Accord 50 mg/ml, oplossing voor injectie of infusie, Oxaliplatine Fresenius Kabi 5 mg/ml concentraat voor oplossing voor infusie

    Disc Medicine

    oesophageal cancer, oesophagogastric junction cancer

    phase 2 small molecule active

    1 trial

  5. Gamma-retroviral vector MP71 MC2 TCR16-3D9

    Disc Medicine

    advanced melanoma or HNSCC

    phase 2 small molecule active

    1 trial

  6. Gazyvaro 1,000 mg concentrate for solution for infusion.

    Disc Medicine

    Sjögren's syndrome

    phase 2 small molecule active

    1 trial

  7. Gazyvaro 1,000 mg concentrate for solution for infusion.

    Disc Medicine

    Primary membranous nephropathy

    phase 2 small molecule active

    1 trial

  8. Giapreza 2.5 mg/ml concentrate for solution for infusion

    Disc Medicine

    Liver cancer (primary or secondary)

    phase 2 small molecule active

    1 trial

  9. Humira 40 mg solution for injection in pre-filled syringe

    Disc Medicine

    Inflammatory Bowel Disease (IBD)

    phase 2 small molecule active

    1 trial

  10. IDP-121 Concentrate for solution for infusion 3 mg/mL

    Disc Medicine

    Unresectable/metastatic Small cell Lung Cancer (SCLC)

    phase 2 small molecule active

    1 trial

  11. IDP-121 Concentrate for solution for infusion 3 mg/mL

    Disc Medicine

    Chronic lymphocytic leukemia (CLL), Any type of B-cell lymphomas, Multiple myeloma (MM)

    phase 2 small molecule active

    1 trial

  12. IL-6 aGVHD Siltuximab: A phase II study to assess the efficacy and tolerability of siltuximab plus corticosteroids in first line treatment of grade III/IV acute graft versus host disease of the liver of/and the gastro-intestinal tract.

    Disc Medicine

    Grade III/IV acute graft versus host disease of the liver of/and the gastro-intestinal tract

    phase 2 other active

    1 trial

  13. IMCIVREE 10 mg/ml solution for injection

    Disc Medicine

    ROHHAD syndrome

    phase 2 small molecule active

    1 trial

  14. IMFINZI 50 mg/mL concentrate for solution for infusion., Ampligen

    Disc Medicine

    Metastatic pancreatic cancer

    phase 2 small molecule active

    1 trial

  15. IPILIMUMAB, MELPHALAN , NIVOLUMAB

    Disc Medicine

    metastasized melonama uveal

    phase 2 small molecule active

    1 trial

  16. Idefirix 11 mg powder for concentrate for solution for infusion

    Disc Medicine

    neuromyelitis optica spectrum disorder, devic disease

    phase 2 small molecule active

    1 trial

  17. Induction of neo-antigen specific T cells by specialized cross-presenting dendritic cells in epithelial ovarian cancer patients treated with neoadjuvant chemotherapy, the NEODOC study

    Disc Medicine

    Ovarian cancer

    phase 2 other active

    1 trial

  18. Irinotecan Accord 20 mg/ml concentraat voor oplossing voor infusie

    Disc Medicine

    Gastric peritoneal metastases

    phase 2 small molecule active

    1 trial

  19. Jardiance 10 mg film-coated tablets, BI 690517, Spironolacton Accord 25 mg filmomhulde tabletten, OMNIPAQUE 350 mg I/ml., AMINOHIPPURIC ACID

    Disc Medicine

    Heart failure, cardiovascular disease, chronic kidney disease

    phase 2 small molecule active

    1 trial

  20. KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Disc Medicine

    Mismatch repair deficient endometrial cancer / uterine cancer

    phase 2 small molecule active

    1 trial

  21. KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Disc Medicine

    Vulvar squamous cell carcinoma

    phase 2 small molecule active

    1 trial

  22. KIMMTRAK 100 micrograms/0.5 mL concentrate for solution for infusion

    Disc Medicine

    Metastatic uveal melanoma with resectable liver metastasis and absence of extra-liver disease

    phase 2 small molecule active

    1 trial

  23. LENALIDOMIDE, PYRIMETHAMINE, TOPIRAMATE

    Disc Medicine

    HIV-1

    phase 2 small molecule active

    1 trial

  24. LENVATINIB, KEYTRUDA 25 mg/mL concentrate for solution for infusion.

    Disc Medicine

    high risk or poor response after chemoradiation and brachytherapy for locally advanced cervix cancer

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources